821767-61-7

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 4-formyl-1H-pyrazole-1-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals, particularly for the production of antipyretic analgesics. Its unique chemical structure and properties make it a valuable component in the development of new and effective medications.
Used in Organic Synthesis:
As an intermediate in organic synthesis, Tert-Butyl 4-formyl-1H-pyrazole-1-carboxylate is utilized in the preparation of a wide range of chemical compounds. Its versatility allows for the creation of various molecules with potential applications in different industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Laboratory Preparations:
Tert-Butyl 4-formyl-1H-pyrazole-1-carboxylate serves as a useful reagent in laboratory settings, where it is employed in the synthesis and modification of other chemical compounds. Its presence in various chemical reactions contributes to the advancement of scientific research and the development of novel compounds with diverse applications.

Upstream product

• 199003-22-0 tert-butyl 4-(hydroxymethyl)-1H-pyrazole-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 35344-95-7 1H-pyrazole-4-carbaldehyde 

Downstream Products

• 1453853-59-2 tert-butyl 4-((4-chloro-3-fluorophenyl)(4-(5-fluoro-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-2-oxopyridin-1(2H)-yl)methyl)-1H-pyrazole-1-carboxylate 
• 1453853-51-4 tert-butyl 4-((4-chloro-3-fluorophenyl)(4-(2-(methylthio)pyrimidin-4-yl)-2-oxopyridin-1(2H)-yl)methyl)-1H-pyrazole-1-carboxylate 
• 1453853-49-0 tert-butyl 4-(chloro(4-chloro-3-fluorophenyl)methyl)-1H-pyrazole-1-carboxylate 

Relevant academic research and scientific papers

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

SERINE/THREONINE KINASE INHIBITORS

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

OPTICALLY ACTIVE TETRAHYDRONAPHTHALENE DERIVATIVE

A compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate thereof or a solvate thereof, which shows not only a C5a receptor antagonistic activity but also high activity in the biological availability, as

HETEROARYLAMINO-PHENYLKETONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS

The present invention relates to compounds that inhibit VEGF receptor tyrosine kinases, especially KDR, pharmaceutical compositions that contain such compounds, methods of treating VEGF receptor kinase-dependent diseases and conditions in mammals using such compounds and composition and methods for their manufacture.